TScan Therapeutics Announces Pause Of Enrollment In Phase 3 ALLOHA-2 Study Of TSC-101 Due To Insufficient Capital; Cuts Workforce About 75%, Extends Runway Into Q4 2027
Share
Why It Matters
TScan Therapeutics ran out of money to continue testing a medicine, so they paused the study and laid off most of their workers to save cash and stay alive until late 2027. When a company makes big cuts like this, it tells you they're in survival mode, not growing mode.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.